Retatrutide, from Soma Corp., is receiving significant attention as a innovative therapy for obesity regulation. This unique compound combines the mechanism of a GLP-1 receptor stimulant and a GIP receptor agonist , aiming to simply promote reduced body fat but also target underlying metabolic is